HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

A new study has found that the groundbreaking new class of weight loss drugs may not only be good at treating diabetes, but ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

The best online providers offer strong support services to help you succeed in your GLP-1 weight loss journey.

Eli Lilly ( LLY -1.63%) and Microsoft ( MSFT 1.20%) are two high-flying dividend stocks in the S&P 500 index. Here's why the ...

Eli Lilly has been making quite a bit of noise thanks to its work in diabetes and obesity. Investors turned on the company, ...

But if a company has been paying dividends for a long time, that can give investors confidence in its ability to continue ...

Lilly's newest cash cow, tirzepatide -- a therapy for type 2 diabetes and weight ... the company has plenty of leeway to ...